Method of synthesis and isolation of solid N-desmethylclozapine and crystalline forms thereof

• US 20050282800A1
• Filed: 03/31/2005
• Published: 12/22/2005
• Est. Priority Date: 04/01/2004
• Status: Abandoned Application

• Current Assignee: Acadia Pharmaceuticals Inc.
• Original Assignee: Acadia Pharmaceuticals Inc.
• Inventors: Blatter, Fritz, Thygesen, Mikkel Boas, Tolf, Bo-Ragnar, Berghausen, Jörg
• Application Number:
  US11/096,756
• Publication Number:
  US 20050282800A1
• Time in Patent Office: Days
• US Class Current: 514/220
• CPC Class Codes: A61P 25/18 Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
• CPC Class Codes: C07D 243/38 [b, e]- or [b, f]-condensed with six-membered rings

Abstract

Disclosed herein are crystalline Forms A, B, C, D, and E of N-desmethylclozapine, methods of preparing the same, pharmaceutical compositions comprising the same, and methods of therapeutic treatment involving N-desmethylclozapine polymorphic forms.

Claims

1. A crystalline N-desmethylclozapine.

2. A composition of matter comprising crystalline N-desmethylclozapine.

3. A crystalline N-desmethylclozapine substantially free of amorphous N-desmethylclozapine.

4. The crystalline N-desmethylclozapine of claim 3 comprising less than 30% amorphous N-desmethylclozapine.

5. The crystalline N-desmethylclozapine of claim 3 comprising less than 25% amorphous N-desmethylclozapine.

6. The crystalline N-desmethylclozapine of claim 3 comprising less than 20% amorphous N-desmethylclozapine.

7. The crystalline N-desmethylclozapine of claim 3 comprising less than 15% amorphous N-desmethylclozapine.

8. The crystalline N-desmethylclozapine of claim 3 comprising less than 10% amorphous N-desmethylclozapine.

9. The crystalline N-desmethylclozapine of claim 3 comprising less than 5% amorphous N-desmethylclozapine.

10. A crystalline N-desmethylclozapine Form A.

11. The crystalline N-desmethylclozapine of claim 10 that produces a powder X-ray diffraction pattern with interplanar d-spacings of 9.9, 6.9, 6.5, 6.3, 6.1, 5.57, 5.09, 4.94, 4.61, 4.47, 4.38, 4.01, 3.74, 3.66, 3.55, 3.45, 3.33, 3.21, 3.08, 3.03, 2.80, and 2.67 (Å

).

12. The crystalline N-desmethylclozapine of claim 10 that produces a powder X-ray diffraction pattern with interplanar d-spacings of 6.5, 6.3, 5.57, 5.09, 4.47, 4.38, 4.01, 3.74, 3.66, 3.55, 3.33, 3.21, and 3.08 (Å

).

13. The crystalline N-desmethylclozapine of claim 10 that produces a powder X-ray diffraction pattern with interplanar d-spacings of 5.57, 5.09, 4.01, 3.66, 3.55, 3.21, and 3.08 (Å

).

14. The crystalline N-desmethylclozapine of claim 10 that produces a powder X-ray diffraction pattern with reflections at 8.9, 12.8, 13.6, 14.0, 14.6, 15.9, 17.4, 17.9, 19.2, 19.9, 20.3, 22.1, 23.8, 24.35, 25.1, 25.8, 26.7, 27.8, 29.0, 29.4, 32.0, and 33.5 °

2θ

.

15. The crystalline N-desmethylclozapine of claim 10 that produces a powder X-ray diffraction pattern with reflections at 13.6, 14.0, 15.9, 17.4, 19.9, 20.3, 22.1, 23.8, 24.35, 25.1, 26.7, 27.8, and 29.0 °

2θ

.

16. The crystalline N-desmethylclozapine of claim 10 that produces a powder X-ray diffraction pattern with reflections at 15.9, 17.4, 22.1, 24.35, 25.1, and 27.8 °

2θ

.

17. A crystalline N-desmethylclozapine Form B.

18. The crystalline N-desmethylclozapine of claim 17 that produces a powder X-ray diffraction pattern with interplanar d-spacings of 8.9, 7.7, 7.1, 6.5, 5.94, 5.85, 5.76, 5.30, 5.17, 4.90, 4.67, 4.48, 4.17, 3.93, 3.87, 3.72, 3.68, 3.55, 3.44, 3.36, 3.26, 3.20, 3.06, 2.75, 2.73, 2.49, 2.45, 2.37, and 2.34 (Å

).

19. The crystalline N-desmethylclozapine of claim 17 that produces a powder X-ray diffraction pattern with interplanar d-spacings of 8.9, 7.7, 7.1, 6.5, 5.94, 5.85, 5.76, 5.30, 5.17, 4.90, 4.67, 4.17, 3.93, 3.87, 3.72, 3.68, 3.55, 3.44, 3.26, 3.20, 3.06, 2.75, 2.73, 2.49, 2.45, 2.37, and 2.34 (Å

) are particularly characteristic.

20. The crystalline N-desmethylclozapine of claim 17 that produces a powder X-ray diffraction pattern with interplanar d-spacings of 7.1, 5.94, 5.30, 5.17, 4.17, 3.93, 3.72, 3.68, 3.44, 3.26, and 3.06 (Å

).

21. The crystalline N-desmethylclozapine of claim 17 that produces a powder X-ray diffraction pattern with reflections at 9.9, 11.4, 12.5, 13.7, 14.9, 15.1, 15.4, 16.7, 17.2, 18.1, 19.0, 19.8, 21.3, 22.6, 23.0, 23.9, 24.2, 25.0, 25.9, 26.5, 27.3, 27.9, 29.1, 32.5, 32.8, 36.0, 36.7, 38.0, and 38.5 °

2θ

.

22. The crystalline N-desmethylclozapine of claim 17 that produces a powder X-ray diffraction pattern with reflections at 9.9, 11.4, 12.5, 13.7, 14.9, 15.1, 15.4, 16.7, 17.2, 18.1, 19.0, 21.3, 22.6, 23.0, 23.9, 24.2, 25.0, 25.9, 27.3, 27.9, 29.1, 32.5, 32.8, 36.0, 36.7, 38.0, and 38.5 °

2θ

.

23. The crystalline N-desmethylclozapine of claim 17 that produces a powder X-ray diffraction pattern with reflections at 12.5, 14.9, 16.7, 17.2, 21.3, 22.6, 23.9, 24.2, 25.9, 27.3, 29.1 °

2θ

.

24. A crystalline N-desmethylclozapine Form C.

25. The crystalline N-desmethylclozapine of claim 24 that produces a powder X-ray diffraction pattern with interplanar d-spacings of 14.2, 13.7, 12.2, 11.7, 7.9, 4.59, 6.9, 6.4, 5.83, 5.42, 5.17, 4.95, 4.59, 4.46, 3.94, 3.63, and 4.59 (Å

).

26. The crystalline N-desmethylclozapine of claim 24 that produces a powder X-ray diffraction pattern with interplanar d-spacings of 12.2, 4.59, 5.17, 4.95, 4.59, 4.46, 3.94, 3.63, and 4.59 (Å

).

27. The crystalline N-desmethylclozapine of claim 24 that produces a powder X-ray diffraction pattern with interplanar d-spacings of 4.59, 4.95, 4.59, 4.46, 3.94, and 4.59 (Å

).

28. The crystalline N-desmethylclozapine of claim 24 that produces a powder X-ray diffraction pattern with reflections at 6.2, 6.5, 7.2, 7.6, 11.3, 19.3, 12.8, 13.9, 15.2, 16.3, 17.1, 17.9, 19.3, 19.9, 22.5, 24.5, and 19.3 °

2θ

.

29. The crystalline N-desmethylclozapine of claim 24 that produces a powder X-ray diffraction pattern with reflections at 7.2, 19.3, 17.1, 17.9, 19.3, 19.9, 22.5, 24.5, and 19.3 °

2θ

.

30. The crystalline N-desmethylclozapine of claim 24 that produces a powder X-ray diffraction pattern with reflections at 19.3, 17.9, 19.3, 19.9, 22.5, and 19.3 °

2θ

.

31. A crystalline N-desmethylclozapine Form D.

32. The crystalline N-desmethylclozapine of claim 31 that produces a powder X-ray diffraction pattern with interplanar d-spacings of 8.6, 7.6, 7.0, 6.4, 6.1, 5.81, 5.52, 5.24, 5.03, 4.95, 4.73, 4.20, 4.04, 3.90, 3.80, 3.70, 3.63, 3.50, 3.42, 3.37, 3.33, 3.26, 3.20, 3.13, 3.04, and 2.71 (Å

).

33. The crystalline N-desmethylclozapine of claim 31 that produces a powder X-ray diffraction pattern with interplanar d-spacings of 8.6, 7.0, 6.4, 5.81, 5.52, 5.24, 5.03, 4.95, 4.73, 4.20, 4.04, 3.90, 3.80, 3.70, 3.63, 3.50, 3.42, 3.37, 3.33, 3.26, 3.20, 3.13, 3.04, and 2.71 (Å

).

34. The crystalline N-desmethylclozapine of claim 31 that produces a powder X-ray diffraction pattern with interplanar d-spacings of 7.0, 5.24, 5.03, 4.20, 4.04, 3.80, 3.70, 3.63, 3.37, and 3.04 (Å

) are most characteristic.

35. The crystalline N-desmethylclozapine of claim 31 that produces a powder X-ray diffraction pattern with reflections at 10.3, 11.6, 12.6, 13.8, 14.5, 15.2, 16.0, 16.9, 17.6, 17.9, 18.7, 21.1, 22.0, 22.8, 23.4, 24.0, 24.5, 25.4, 26.1, 26.4, 26.8, 27.3, 27.8, 28.5, 29.3, and 33.0 °

2θ

.

36. The crystalline N-desmethylclozapine of claim 31 that produces a powder X-ray diffraction pattern with reflections at 10.3, 12.6, 13.8, 15.2, 16.0, 16.9, 17.6, 17.9, 18.7, 21.1, 22.0, 22.8, 23.4, 24.0, 24.5, 25.4, 26.1, 26.4, 26.8, 27.3, 27.8, 28.5, 29.3, and 33.0 °

2θ

.

37. The crystalline N-desmethylclozapine of claim 31 that produces a powder X-ray diffraction pattern with reflections at 12.6, 16.9, 17.6, 21.1, 22.0, 23.4, 24.0, 24.5, 26.4, and 29.3 °

2θ

.

38. A crystalline N-desmethylclozapine Form E.

39. The crystalline N-desmethylclozapine of claim 38 that produces a powder X-ray diffraction pattern with interplanar d-spacings of 12.6, 11.8, 11.0, 7.3, 7.0, 6.7, 6.4, 5.90, 5.60, 5.35, 4.95, 4.62, 4.44, 4.01, 3.94, 3.75, 3.37, and 3.00 (Å

).

40. The crystalline N-desmethylclozapine of claim 38 that produces a powder X-ray diffraction pattern with interplanar d-spacings of 4.95, 4.62, 4.44, 4.01, 3.94, and 3.75 (Å

).

41. The crystalline N-desmethylclozapine of claim 38 that produces a powder X-ray diffraction pattern with interplanar d-spacings of 4.95, 4.62, and 4.44 (Å

) are most characteristic.

42. The crystalline N-desmethylclozapine of claim 38 that produces a powder X-ray diffraction pattern with reflections at 7.0, 7.5, 8.0, 12.1, 12.7, 13.3, 13.9, 15.0, 15.8, 16.6, 17.9, 19.2, 20.0, 22.1, 22.6, 23.7, 26.4, and 29.7 °

2θ

.

43. The crystalline N-desmethylclozapine of claim 38 that produces a powder X-ray diffraction pattern with reflections at 17.9, 19.2, 20.0, 22.1, 22.6, and 23.7 °

2θ

.

44. The crystalline N-desmethylclozapine of claim 38 that produces a powder X-ray diffraction pattern with reflections at 17.9, 19.2, and 20.0 °

2θ

.

45. A pharmaceutical composition comprising crystalline N-desmethylclozapine and a pharmaceutically acceptable carrier, eluent, or excipient.

46. The pharmaceutical composition of claim 45, wherein said crystalline N-desmethylclozapine is substantially free of amorphous N-desmethylclozapine.

47. The pharmaceutical composition of claim 45, wherein said crystalline N-desmethylclozapine is N-desmethylclozapine Form A.

48. The pharmaceutical composition of claim 45, wherein said crystalline N-desmethylclozapine is N-desmethylclozapine Form B.

49. The pharmaceutical composition of claim 45, wherein said crystalline N-desmethylclozapine is N-desmethylclozapine Form C.

50. The pharmaceutical composition of claim 45, wherein said crystalline N-desmethylclozapine is N-desmethylclozapine Form D.

51. The pharmaceutical composition of claim 45, wherein said crystalline N-desmethylclozapine is N-desmethylclozapine Form E.